 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C30H33NO |
| Molar mass | 423.600 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JWH-371 ([5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is asynthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of theCB1 (Ki = 42 ± 1nM) andCB2 (Ki = 64 ± 2nM) receptors, binding ~1.5 times stronger to the CB1 receptor than the CB2 receptor. JWH-371 was first synthesized in 2006 byJohn W. Huffman and colleagues to examine the nature of ligand binding to theCB1 receptor.[1]
In the United States JWH-371 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-371.[2][3][4][5]
In Canada, JWH-371 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under theControlled Drugs and Substances Act.[citation needed]
In the United Kingdom, JWH-371 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under theMisuse of Drugs Act 1971.[citation needed]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
